Skip to main content
SpringerLink
Log in

Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis. Since most clinical trials examined etanercept in combination with other drugs, the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established. This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy. These patients were treated with etanercept at a subcutaneous dose of 25 mg, twice a week, for 12 weeks. All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores. At 4, 8, and 12 weeks after treatment, the response rates (PASI75) were 0%, 21.31%, and 40.98%, respectively. It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate- to-severe plaque psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol, 2010,146(1):46–54

    Article  PubMed  CAS  Google Scholar 

  2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet, 2007,370(9583):263–271

    Article  PubMed  CAS  Google Scholar 

  3. Liu XX, Feng AP, He YM, et al. Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis. J Huazhong Univ Sci Technol [Med Sci], 2016,36(1):132–136

    Article  CAS  Google Scholar 

  4. Busard C, Zweegers J, Limpens J, et al. Combined use of systemic agents for psoriasis: a systematic review. JAMA Dermatol, 2014,150(11):1213–1220

    Article  PubMed  Google Scholar 

  5. Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol, 2007,25(6):574–580

    Article  PubMed  Google Scholar 

  6. Lima XT, Oliveira RT, Braga FG, et al. Circulating levels of chemokines in psoriasis. Autoimmunity, 2015,48(1):57–60

    Article  PubMed  CAS  Google Scholar 

  7. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature, 2007,445(7128):648–651

    Article  PubMed  CAS  Google Scholar 

  8. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol, 2009,129(1):79–88

    Article  PubMed  CAS  Google Scholar 

  9. Antiga E, Volpi W, Cardilicchia E, et al. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol, 2012,32(6):1221–1232

    Article  PubMed  CAS  Google Scholar 

  10. Tonel G, Conrad C, Laggner U, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol, 2010,185(10):5688–5691

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Witte E, Kokolakis G, Witte K, et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol, 2014,134(11):2757–2767

    Article  PubMed  CAS  Google Scholar 

  12. Schotte H, Schluter B, Willeke P, et al. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. Rheumatology, 2004,43(8):960–964

    Article  PubMed  CAS  Google Scholar 

  13. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med, 2003,349(21):2014–2022

    Article  PubMed  CAS  Google Scholar 

  14. Puig L, Camacho Martinez FM, Gimeno Carpio E, et al. Efficacy and safety of clinical use of etanercept for the treatment of moderate-to-severe psoriasis in Spain: results of a multicentric prospective study at 12 months follow-up. Dermatology, 2012,225(3):220–230

    Article  PubMed  CAS  Google Scholar 

  15. Maria Fernandez-Torres R, Paradela S, Fonseca E. Long-term efficacy of etanercept for plaque-type psoriasis and estimated cost in daily clinical practice. Value Health, 2015,18(8):1158–1161

    Article  PubMed  Google Scholar 

  16. Kivelevitch D, Mansouri B, Menter A. Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics, 2014,8:169–182

    PubMed  PubMed Central  CAS  Google Scholar 

  17. Tsai YC, Tsai TF. A review of clinical trials of biologic agents and small molecules for psoriasis in Asian subjects. G Ital Dermatol Venereol, 2016,151(4):412–431

    PubMed  Google Scholar 

  18. Chiu HY, Wang TS, Cho YT, et al. Etanercept use for psoriasis in Taiwan: a case series study. Int J Dermatol, 2013,52(6):673–680

    Article  PubMed  Google Scholar 

  19. Wu YF SY, Yang CH, Huang YH. Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. Dermatol Sin, 2013,31:49–53

    Article  Google Scholar 

  20. Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica, 1978,157(4):238–244

    Article  PubMed  CAS  Google Scholar 

  21. Campa M, Mansouri B, Warren R, et al. A Review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther, 2016,6(1):1–12

    Article  Google Scholar 

  22. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med, 1999,130(6):478–486

    PubMed  CAS  Google Scholar 

  23. Nast A, Jacobs A, Rosumeck S, et al. Efficacy and safety of systemic long-term treatments for moderateto-severe psoriasis: A systematic review and meta-analysis. J Invest Dermatol, 2015,135(11):2641–2648

    Article  PubMed  CAS  Google Scholar 

  24. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderateto-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet, 2015,386(9993):541–551

    Article  PubMed  CAS  Google Scholar 

  25. Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol, 2016,74(2):280–287

    Article  PubMed  CAS  Google Scholar 

  26. Gottlieb AB, Leonardi CL, Goffe BS, et al. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database. J Am Acad Dermatol, 2006,54(3 Suppl 2):S92–100

    Article  PubMed  Google Scholar 

  27. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol, 2005,152(6):1304–1312.

    Article  PubMed  CAS  Google Scholar 

  28. Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial). J Dermatolog Treat, 2013,24(3):169–178

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Dermatology, Chinese PLA General Hospital, Medical College of Chinese PLA, Beijing, 100853, China

    Fang Xie  (解 方), Rui Wang  (王 睿), Zi-gang Zhao  (赵梓纲), Xian-fu Meng  (孟宪芙), Bi-wen Lin  (林碧雯), Wen-juan Wang  (王文娟), Xiang-yu Ding  (丁香玉), Yi Yang  (杨 怡), Hua Zhao  (赵 华), Cheng-xin Li  (李承新), Heng-jin Li  (李恒进) & Yong Zhou  (周 勇)

  2. Department of Dermatology, Affiliated Hospital of Hebei United University, Medical College of Chinese PLA, Tangshan, 063000, China

    Jie Yang  (杨 洁)

Authors
  1. Fang Xie  (解 方)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rui Wang  (王 睿)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zi-gang Zhao  (赵梓纲)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xian-fu Meng  (孟宪芙)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bi-wen Lin  (林碧雯)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jie Yang  (杨 洁)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wen-juan Wang  (王文娟)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiang-yu Ding  (丁香玉)
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yi Yang  (杨 怡)
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hua Zhao  (赵 华)
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Cheng-xin Li  (李承新)
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Heng-jin Li  (李恒进)
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yong Zhou  (周 勇)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Zhou  (周 勇).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xie, F., Wang, R., Zhao, Zg. et al. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study. CURR MED SCI 37, 943–947 (2017). https://doi.org/10.1007/s11596-017-1832-7

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-017-1832-7

Key words

Search

Navigation